Mdxhealth Completes Acquisition of Exosome Diagnostics from Bio-Techne

Mdxhealth has closed its acquisition of Exosome Diagnostics from Bio-Techne, including the ExoDx Prostate test. The total consideration is $15 million, with $5 million in stock paid at closing and $2.5 million to be paid annually over 4 years. The acquisition is expected to enhance mdxhealth's precision diagnostics capabilities and expand its offerings in urologic cancers and other diseases.

MdxHealth (NASDAQ: MDXH), a precision diagnostics company, has completed the acquisition of Exosome Diagnostics, Inc. from Bio-Techne Corporation. The acquisition includes the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets. The total acquisition value is $15 million, structured as $5 million in stock paid at closing, with the remaining $10 million to be paid over four years in annual installments of $2.5 million (50% cash, 50% optional cash or stock) Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne^[1].

The acquisition is expected to enhance MdxHealth's precision diagnostics capabilities and expand its offerings in urologic cancers and other diseases. The ExoDx Prostate test is a CLIA-certified diagnostic tool that assists physicians in the diagnosis and prognosis of prostate cancer. This acquisition aligns with MdxHealth's strategy to leverage its proprietary genomic, epigenetic, and exosomal technologies to provide actionable molecular information for personalized patient diagnosis and treatment.

MdxHealth's U.S. headquarters and laboratory operations are located in Irvine, California, with additional operations in Waltham, Massachusetts and Plano, Texas. The European headquarters are in Herstal, Belgium. The acquisition was advised by XMS Capital Partners, with legal counsel provided by K&L Gates and Baker McKenzie Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne^[1].

The acquisition is subject to certain risks and uncertainties, including the ability to successfully market and obtain adequate reimbursement for the products, regulatory approvals, and the realization of expected synergies and benefits Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne^[1].